Merck's Q1 results showed strong performance across its three major businesses, with 6% growth in pharmaceuticals and vaccines, 7% growth in Consumer Care, and 8% growth in Animal Health. The company's key growth drivers, such as JANUVIA and GARDASIL, continued to perform well, and its pipeline has several promising products, including odanacatib and Suvorexant. However, the company faces challenges, including the upcoming patent expiry of SINGULAIR and biosimilar competition for REMICADE. Management's tone was optimistic, and they expressed confidence in the company's ability to manage these challenges and deliver long-term shareholder value.

[1]